Armata Pharmaceuticals (ARMP) Change in Accured Expenses (2013 - 2026)

Armata Pharmaceuticals has disclosed Change in Accured Expenses across 14 years of filings, most recently posting -$352000.0 for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$352000.0, up 36.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $112000.0 (up 102.5% YoY), and the FY2025 annual result was -$89000.0, up 97.63% from the prior year.
• Change in Accured Expenses came in at -$352000.0 for Q1 2026 at Armata Pharmaceuticals, down from $348000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.9 million in Q4 2022 to a low of -$2.3 million in Q2 2024.
• The 5-year median for Change in Accured Expenses is -$265000.0 (2025), against an average of -$93588.2.
• Across the five-year window, Change in Accured Expenses surged 420.06% in 2023 and slumped 407.22% in 2025, its largest moves.
• Armata Pharmaceuticals' Change in Accured Expenses stood at $2.9 million in 2022, then plunged by 125.53% to -$739000.0 in 2023, then slumped by 133.29% to -$1.7 million in 2024, then surged by 120.19% to $348000.0 in 2025, then tumbled by 201.15% to -$352000.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$352000.0 (Q1 2026), $348000.0 (Q4 2025), and $381000.0 (Q3 2025), per Business Quant data.